Sexual HealthAlso known as: Vyleesi, PT-141, bremelanotide acetate
Bremelanotide
FDA-approved MC4R agonist (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Derived from Melanotan II but redesigned for sexual function with reduced tanning.
Half-Life
~2.7 hours
Dose Range
1.75 mg (FDA approved dose)
Frequency
As needed (≥45 min before activity, max 1×/24 hours, ≤8×/month)
Vial Sizes
10 mg
Mechanism of Action
Melanocortin-4 receptor agonist that activates central arousal pathways in the hypothalamus and limbic system. Unlike PDE5 inhibitors, works through the CNS rather than peripheral blood flow. Produces dose-dependent nausea mediated by area postrema MC4R.
Source: PMID: 31298622 (RECONNECT Phase 3)
Dosing Protocol
| Typical Dose | 1.75 mg (FDA approved dose) |
| Frequency | As needed (≥45 min before activity, max 1×/24 hours, ≤8×/month) |
| Half-Life | ~2.7 hours |
| Common Vial Sizes | 10 mg |
Reconstitution Example
Vial
10 mg
Water
2 mL
Concentration
5 mg/mL
Per Unit (100u syringe)
50 mcg
Dose of 500 mcg = 10 units on a 100-unit insulin syringe
Dosing Quick Reference
Bremelanotide— Dosing Guide
Dose Range
1.75 mg (FDA approved dose)
Half-Life
~2.7 hours
Frequency
As needed (≥45 min before activity, max 1×/24 hours, ≤8×/month)
Route
Subcutaneous
10 mg vial
💧 2 mL BAC water|📐 5 mg/mL concentration|💉 50 mcg/unit (100u syringe)
Sexual Healthcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code